{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-323729","form_type":"8-K","ticker":"GKOS","cik":"0001192448","company_name":"GLAUKOS Corp","filed_at":"2026-07-29T20:10:17+00:00","discovered_at":"2026-07-29T20:11:00.329915+00:00","generated_at":"2026-07-29T20:11:32.225916+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Glaukos Q2 net sales $185.6M (+50% YoY); raises FY2026 guidance to $680-700M","bullets":["Record net sales $185.6M, up 50% YoY; U.S. glaucoma sales $118.5M (+64%).","GAAP net loss $18.4M ($0.31/sh); non-GAAP net loss $8.3M ($0.14/sh), improved from $19.7M loss a year ago.","Gross margin 82% (non-GAAP 85%), up from 78% (83%) YoY.","Raised 2026 net sales guidance to $680-700M from prior $620-635M.","Cash $289.3M, no debt; cites iDose TR and Epioxa as growth drivers."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-323729","json":"https://secwatch.observer/filing/0001193125-26-323729.json","markdown":"https://secwatch.observer/filing/0001193125-26-323729.md","text":"https://secwatch.observer/filing/0001193125-26-323729.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1192448/000119312526323729/0001193125-26-323729-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1192448/000119312526323729/gkos-20260729.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-07-29T20:11:32.225916+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}